BTA
Botulinum Toxin Type A (BTA) is a purified protein from the bacterium Clostridium Botulinum that effectively and safely:
- Blocks nerve impulses responsible for wrinkles formation at the forehead, frown lines and crow’s feet areas.
- Reduces bulky masseter muscles (chewing muscles) to create V-shaped face by reducing square jawline.
Unlike other invasive procedures, BTA is relatively safe as it is reversible and of non-permanent effect. BTA is virtually painless method towards a youthful and radiant skin.
We currently have 2 BTA types:
- onabotulinumtoxinA (Botox®; Botox Cosmetic, Allergan, Irvine, CA, USA)
- incobotulinumtoxinA (Xeomin®; Merz Pharmaceuticals, Frankfurt, Germany)
Xeomin®
Xeomin® is a prescription medication injected into muscles and used to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines) in adults. Xeomin® contains botulinum toxin type A, a protein purified from the bacterium Clostridium Botulinum.
You may begin to see visible smoothing as early as 3-4 days after injection. The median first onset of effect was less than a week.
The maximum effect occurred at 30 days. The typical duration of effect was up to 3 months in clinical trials but may last significantly longer or shorter in individual patients.
Xeomin® was proven effective in two randomized, double-blind, multicenter, placebo-controlled clinical trials of 547 healthy, adult patients. The average age of patients in the study was 46 years.
Patients received 20 Units of Xeomin® and were classified as responders if they had a 2-grade improvement on a 4-point scale as assessed by the physician and patient.
Using these criteria, treatment success was higher with Xeomin® than placebo on Day 30 in both studies (60% and 48% vs. 0% for placebo in both studies).
Based on these trials, Xeomin® received FDA approval for use in glabellar lines in 2011.
Xeomin® is made through a unique precision manufacturing process that isolates the therapeutic component of the molecule and removes the accessory proteins that don’t play an active role in treatment.
Xeomin® is a highly purified neurotoxin. Studies have not been performed to determine whether the presence or absence of accessory proteins has a long-term effect on safety or efficacy.